4-Antibody AG closes CHF 6 Million Series A financing and appoints Sijmen de Vries as CEO
4-Antibody announced the closing of a CHF 6 million Series A financing and the appointment of Sijmen de Vries MD, MBA as its new CEO.
The Series A financing was provided by a consortium of existing investors including Biomedinvest AG (CH), Grazia Equity (D), Life Science Partners (NL) and Mulligan Biocapital (D). Proceeds will be used to develop internal pipeline projects initially to pre-clinical proof of concept and establish licensing partnerships with biotech and pharma partners.
Sijmen joins 4- Antibody from Morphochem AG (Munich, Germany), where he was CEO and, after successfully re-focusing the business on antibiotic development and steering its lead hospital antibiotic through pre-clinical development, he merged the company with Biovertis AG. Previous to that, he held various senior management positions at Novartis Pharma AG and SmithKline Beecham. Dr de Vries succeeds Dr Ulf Grawunder, who as co-founder of the company successfully led the company through its initial growth phases and continues to serve the company as its CSO.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.